DrugMapper

Search structure


Trade Names:	GLEOSTINE
Synonyms:	CCN-U CCNU CEENU GLEOSTINE LOMUSTINA NSC-79037
Status:	Approved (1976)
Entry Type:	Small molecule
Molecule Category:	UNKNOWN
ATC:	L01AD02
UNII:	7BRF0Z81KG


InChI Key	GQYIWUVLTXOXAJ-UHFFFAOYSA-N
Smile	O=NN(CCCl)C(=O)NC1CCCCC1
InChI	InChI=1S/C9H16ClN3O2/c10-6-7-13(12-15)9(14)11-8-4-2-1-3-5-8/h8H,1-7H2,(H,11,14)

Action	Mechanism of Action	Reference
INHIBITOR	DNA inhibitor

Targets	EC50(nM)	IC50(nM)	Kd(nM)	Ki(nM)	Inhibition(%)
Enzyme Transferase	-	-	-	-	21.68
Epigenetic regulator Eraser Histone deacetylase HDAC class IIb	-	-	-	-	-14.47--6.48

Mesh Heading	Maximum Phase	Mesh ID	Reference
Brain Neoplasms	4	D001932	ClinicalTrials
Multiple Myeloma	3	D009101	ClinicalTrials
Medulloblastoma	3	D008527	ClinicalTrials
Paraganglioma	3	D010235	ClinicalTrials
Glioblastoma	3	D005909	ClinicalTrials
Leukemia, Myeloid, Acute	3	D015470	ClinicalTrials
Astrocytoma	3	D001254	ClinicalTrials
Central Nervous System Neoplasms	3	D016543	ClinicalTrials
Gliosarcoma	3	D018316	ClinicalTrials
Neoplasms, Plasma Cell	3	D054219	ClinicalTrials
Lymphoma, Non-Hodgkin	2	D008228	ClinicalTrials
Melanoma	2	D008545	ClinicalTrials
Kidney Neoplasms	2	D007680	ClinicalTrials
Lung Neoplasms	2	D008175	ClinicalTrials
Lung Neoplasms	2	D008175	ClinicalTrials
Breast Neoplasms	2	D001943	ClinicalTrials
Glioma	2	D005910	ClinicalTrials
Lymphoma	2	D008223	ClinicalTrials
Bone Neoplasms	2	D001859	ClinicalTrials
Uveal Melanoma	2	D000098943	ClinicalTrials
Spinal Cord Neoplasms	2	D013120	ClinicalTrials
Melanoma	2	D008545	ClinicalTrials
Bone Neoplasms	2	D001859	ClinicalTrials
Pancreatic Neoplasms	2	D010190	ClinicalTrials
Sarcoma	2	D012509	ClinicalTrials
Neoplasm Metastasis	2	D009362	ClinicalTrials
Lymphoma, AIDS-Related	2	D016483	ClinicalTrials

Level 3

Level 4

Level 5

Level 6

Indication

Mechanism of Action

Primary Target

Target Level

System Organ Classification (SOC)

	Relative Frequency (%)
General disorders and administration site conditions	11.88
Nervous system disorders	11.39
Neoplasms benign, malignant and unspecified (incl cysts and polyps)	7.43
Injury, poisoning and procedural complications	6.93
Skin and subcutaneous tissue disorders	6.93
Infections and infestations	6.44
Investigations	6.44
Blood and lymphatic system disorders	5.94
Vascular disorders	5.45
Eye disorders	4.46
Psychiatric disorders	4.46
Respiratory, thoracic and mediastinal disorders	4.46
Gastrointestinal disorders	3.96
Immune system disorders	3.47
Hepatobiliary disorders	2.97
Metabolism and nutrition disorders	2.97
Musculoskeletal and connective tissue disorders	2.48

LOMUSTINE


Active Pharmaceutical Ingredients (APIs) Scaffolds	Exact Similarity SubStructure	Threshold (%) >= 70